<http://webisa.webdatacommons.org/prov/43850633>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/111505856> .
<http://webisa.webdatacommons.org/111505856>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/111505856>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<clinicaltrials.gov> .
<http://webisa.webdatacommons.org/111505856>	<http://www.w3.org/ns/prov#value>	"Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to Omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)" .